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Abstract
Corticosteroids are still the cornerstone of treatment for patients with sarcoidosis requiring systemic
therapy. However, alternative agents and especially methotrexate may be considered for patients
with refractory disease or requiring prolonged treatment with intolerable side effects. Although
bioagent therapies have hitherto not clearly demonstrated superior efficacy and safety over
corticosteroids in pulmonary sarcoidosis, infliximab may modestly improve lung function in patients
with active disease resistant to steroids. Further studies will be needed to assess both safety and
efficacy of infliximab in pulmonary sarcoidosis. Infliximab may be considered in a limited number of
patients with severe extrapulmonary systemic manifestations of sarcoidosis, with careful individual
evaluation of the risk-benefit ratio.
Introduction and context
Treatment decision in sarcoidosis is based on the severity
or duration of disease or both (e.g., acute or chronic
sarcoidosis, the latter corresponding to active disease
persisting beyond 5 years from the time of diagnosis) [1].
While no treatment is necessary in a majority of patients,
corticosteroid therapy is the mainstay of treatment for
those who require systemic therapy. Although the dose
of steroids largely varies among centres and is based on
experience rather than evidence, most clinicians use
approximately 0.5 mg/kg per day (30-40 mg per day) of
prednisone or equivalent as a starting daily dose in
chronic sarcoidosis [2]. After maximum improvement
has been achieved, corticosteroid therapy is slowly
tapered to maintenance therapy (10-15 mg or approxi-
mately 0.25 mg/kg daily) in order to establish the
minimal dose that controls disease activity; this requires
regular reassessment of pulmonary symptoms, chest
radiographs, and pulmonary function [2]. The disease
may be considered refractory if improvement has been
documented following 0.5 mg/kg per day prednisone
treatment for at least 3-6 months.
Alternative agents may be used for patients with disease
refractory to corticosteroid therapy (e.g., with symptoms
not controlled or worsening despite adequate corticos-
teroid therapy), for those requiring long-term high-dose
treatment for chronic disease, or for those who cannot
tolerate corticosteroid side effects. When bioagent
therapy is being considered, the decision analysis
approach should include the risk of long-term corticos-
teroid therapy at the maintenance dose and that of
potentially toxic alternative therapy. Corticosteroid
dependence should not be considered a treatment failure
that systematically requires steroid-sparing agents;
indeed, a low-dose corticosteroid treatment when well
tolerated may be superior to bioagent therapies, which
may cause significant, albeit different, adverse events.
Whether follow-up without therapy is possible or
whether therapy is mandatory should be systematically
re-evaluated when considering alternative therapy.
Methotrexate (10 mg/week) has demonstrated steroid-
sparing activity in patients with acute [3] and chronic [4]
sarcoidosis, with a cumulative risk of hepatotoxicity,
and is considered the first-choice alternative to
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therapy and other non-bioagent alternative drugs [1] is
beyond the scope of this review. Long-term monitoring
is required for both response to therapy and toxicity
regardless of the drug used.
Recent advances
Two anti-tumour necrosis factor-alpha (TNF-a) therapies
have been evaluated in sarcoidosis (Tables 1 and 2). Two
studies using etanercept failed to show a treatment
benefit in patients with either progressive pulmonary
disease, using a composite endpoint of dyspnea,
pulmonary function, and chest radiograph [5], or
methotrexate-resistant, corticosteroid-treated ocular sar-
coidosis, using the steroid-sparing effect and global
ocular assessment as an endpoint [6]. Both exploratory
studies suffered significant methodological limitations,
especially the absence of a control group [5] and small
sample size [6]. Diffusion of etanercept into tissues,
especially the vitreous, may also be limited [6]. There-
fore, etanercept does not seem to be effective in most
patients with chronic sarcoidosis.
In contrast, two retrospective series reported sympto-
matic improvement in most patients receiving infliximab
[7,8]. Although the level of evidence was low, efficacy
was suggested in patients with chronic multiorgan
extrapulmonary disease, especially lupus pernio, uveitis,
and neurosarcoidosis, refractory to oral corticosteroids or
with intolerable side effects [7,8]. Infliximab was also
shown to be beneficial in lupus pernio [9] and chronic
inflammatory eye disease in sarcoidosis, including in
patients who had not responded to etanercept [10].
Nineteen patients with chronic active pulmonary sarcoi-
dosis (stage II-IV) who had received corticosteroids for at
least 3 months with suboptimal response or intolerance
were included in a randomised trial [11], and 13 of them
received infliximab. No significant difference was
observed between groups for the primary endpoint
(i.e., the relative change in vital capacity 6 weeks after
initiation of treatment). No change was found in the
secondary endpoints, including radiologic changes,
health-related quality of life, and dyspnea scores.
However, the study was underpowered due to insuffi-
cient accrual. Although not significant, the change in
vital capacity in treated patients was paralleled by a trend
toward improved vital capacity in the subjects in the
placebo group during the open-label treatment in the
second phase of the study. Of note, one patient receiving
infliximab had pneumonia, and another developed
recurrent cellulitis.
In a larger phase II randomised controlled trial in 138
patients with stable chronic pulmonary sarcoidosis
(radiographic stage II-III) [12], infliximab therapy in
addition to a stable dose of background corticosteroids
or immunosuppressive therapy or both was associated
with a 2.5% mean increase in forced vital capacity at
week 24 versus 0 in controls (P = 0.038). Post hoc analysis
identified the subgroups that benefited the most from
this therapy, including those with more severe disease.
The clinical relevance of the modest and transitory
improvement in lung function, though statistically
significant, was unclear. No improvement was obtained
in secondary endpoints. Patients with phase IV or
cavitary sarcoidosis or both were not included. Evalua-
tion of severity of extrapulmonary involvement used a
new, non-validated tool [12], which may not adequately
reflect clinical severity as required for decision analysis
[13]. The small magnitude of improvement (with
potential underestimation of the treatment effect [13])
may be partly due to selection bias, with exclusion of
patients with the most severe disease [13,14] and
inclusion of patients with stable disease already receiving
at least 10 mg/day of prednisone.
The effectiveness of infliximab therapy in chronic granu-
lomatous disease (such as sarcoidosis and Crohn’s
disease) has been hypothesised to be related to its
mechanism of action, whereby it binds both free TNF-a
and cell surface TNF-a (the latter being involved in
complement-mediated cell lysis and antibody-dependent
cell-mediated cytotoxicity as well as apoptosis induction
ofactivatedlymphocytes),incontrasttoetanercept,which
binds soluble but not surface molecules [15].
Table 1. Available anti-tumour necrosis factor-alpha therapies
Drug Mechanism of action Route Dosage
Adalimumab Humanised monoclonal anti- TNF-a antibody Subcutaneous 3-5 mg/kg every 2 weeks
Etanercept Fusion protein of ligand-binding domain of human TNF-a receptor-I and
human Fc fraction of IgG1
Subcutaneous 25 mg twice weekly
Infliximab Chimeric mouse/human monoclonal IgG1 anti-TNF-a antibody Intravenous 3-5 mg/kg, then 2 weeks later, then every
1-2 months
TNF-a, tumour necrosis factor-alpha.
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with the anti-TNF-a adalimumab [16,17], and trials
are currently being conducted (NCT00311246,
NCT00274352). Of note, the paradoxical development
of sarcoidosis has rarely been reported during treatment
with all three available TNF-a antagonists, an event
potentially linked to cytokine disequilibrium [18-24].
In view of the accumulated evidence, limitations of
published trials using anti-TNF-a antibodies suffer from
several flaws, including an inadequate target that does
not include membrane-bound TNF-a [5,6], inadequate
retrospective design [7,8], inadequate patient population
with stable rather than progressive pulmonary disease
[12], and insufficient sample size and power [11].
Trials are under way using golimumab, a fully
human monoclonal antibody directed against
TNF-a (NCT00955279); ustekinumab, a human anti-
interleukin-12/interleukin-23 monoclonal antibody
Table 2. Summary of the main studies of anti-tumour necrosis factor-alpha therapy in sarcoidosis
Reference Drug Design Indication Primary endpoint Results and comments
[5] Etanercept Open-label, phase II, 12
months; n = 17
Progressive stage II-III lung
disease
Composite endpoint Early termination of study for
lack of efficacy
Nasopharyngeal plasmocytoma
and intestinal lymphoma
developed
[6] Etanercept Double-blind randomised
controlled trial, 6 months;
n=1 8
Ocular sarcoidosis with
ongoing inflammation in the
eyes
Corticosteroid-sparing effect Lack of steroid-sparing effect
Lack of ophthalmology global
improvement
Methotrexate-resistant,
corticosteroid-dependent
disease
[8] Infliximab Retrospective series,
infliximab 5 mg/kg at weeks
0, 2 and 6, then every
8 weeks; n = 10
Patients with drug failure or
intolerable side effects
Indication of therapy
extrapulmonary (skin disease
in 6 of 10)
Heterogeneous individual
retrospective clinical
assessment
Steroid-sparing effect
Symptomatic improvement in
9 of 10 patients, objective
improvement in all
10 patients
Steroid-sparing effect obtained
Angioimmunoblastic
lymphoma developed
[7] Infliximab Retrospective series;
infliximab 3 mg/kg at weeks 0,
2, 4, 6, 10 and 14; n = 12
Chronic multiorgan
sarcoidosis, refractory or
intolerant to corticosteroids
or alternative drugs
Heterogeneous individual
retrospective assessment
Some clinical or imaging
improvement in all patients
Low-quality evidence
Recurrence of symptoms upon
discontinuation of treatment
Myeloma developed
[11] Infliximab Phase II, double-blind
randomised controlled trial,
38 weeks, n = 19; infliximab
5 mg/kg or placebo at weeks
0 and 2, then infliximab at
weeks 6 and 14
Chronic active pulmonary
sarcoidosis, stage II-IV
VC 50-80% of predicted
Patients having received
corticosteroids for ≥3
months, with suboptimal
response or intolerance
Mean relative change in VC at
week 6
Non-significant relative change
in VC (15.2% ± 9.9% with
infliximab versus
8.4% ± 3.3% with placebo,
P = 0.65)
No change in secondary
endpoints
19 included patients (42
planned); underpowered trial
One death possibly related to
infliximab
[12,14] Infliximab Phase II, double-blind rando-
mised controlled trial; 1:1:1
to receive placebo, infliximab
3 mg/kg or infliximab 5 mg/kg
at weeks 0, 2, 6, 12, 18 and
24; n = 138
Chronic stable pulmonary
sarcoidosis, stage II-III
FVC 50-85% of predicted
Patients receiving ≥10 mg/day
of prednisone or immuno-
suppressive therapy or both
68% of patients with
extrapulmonary involvement
Change in FVC at week 24
Post hoc analysis of predefined
secondary endpoint ePOST
FVC improvement by 2.5% at
week 24 versus 0 in controls
(P = 0.038)
Post hoc analysis identified
subgroups that benefited most
from therapy
Significant improvement of
ePOST score at 24 weeks, not
maintained after treatment
discontinuation
Adverse events included
pneumonia (4.4%), skin
squamous cell carcinoma and
epitheliod sarcoma
ePOST, extrapulmonary organ severity tool; FVC, forced vital capacity; VC, vital capacity.
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posed of the Fc fraction of human immunoglobulin
G1 fused to the extracellular domain of cytotoxic
T-lymphocyte antigen 4 (NCT00739960), an inhibitory
molecule expressed on the surface of helper T cells. One
report of improvement using rituximab has been
published [25], although sarcoidosis is not a B cell-
driven or autoimmune disease.
Implications for clinical practice
Available evidence does not support the use of etanercept
in sarcoidosis. The experience with adalimumab is too
limited to draw conclusions in sarcoidosis. Infliximab
may improve lung function in patients with active
pulmonary sarcoidosis resistant to steroids, but with
modest and clinically debatable benefit. Long-term
studies will be needed to assess both safety and efficacy
of infliximab in patients with intractable active disease,
in whom corticosteroids are either not effective or not
tolerated. Anti-TNF-a therapy should be further evalu-
ated in patients with progressive disease, who may be
more apt to benefit from therapy [12], as suggested by a
preliminary underpowered negative study [11]. How-
ever, severity scores [14,26] need to be validated
prospectively with regard to prognosis.
Pending further evidence, corticosteroids remain the
cornerstone of therapy in sarcoidosis. The use of
infliximab in sarcoidosis can be discussed on an
individual basis with careful evaluation of the risk-
benefit ratio, and should preferably be considered in the
context of randomised clinical trials. Infliximab may be
used in patients with progressive disease refractory to
corticosteroids, especially in the context of lupus pernio,
intractable uveitis, or neurosarcoidosis. Infliximab is
unlikely to provide significant benefit in patients with
severe but stable stage IV pulmonary disease. Current
risk-benefit analysis suggests that infliximab be used
preferably as third-line therapy (after failure of metho-
trexate as second-line therapy). In such a situation, it is
preferable that low-dose corticosteroids be continued in
association with infliximab. There are no clinical data to
support the concomitant use of methotrexate and
infliximab in sarcoidosis, although the possibility of
blocking antibodies to infliximab during treatment
prompts some clinicians to use concomitant low-dose
methotrexate. Methotrexate should be preferred to
bioagent therapy in patients with intolerable side effects
of corticosteroids and who require maintenance of
therapy; infliximab should currently not be considered
the steroid-sparing agent of choice in sarcoidosis.
Although TNF-a antagonists appear to be relatively safe
(with a safety profile quite distinct from that of systemic
corticosteroids), concerns that anti-TNF-a therapy might
increase the risk of tumour may limit the use of these
agents in the future, and careful evaluation of this
potential risk is warranted. Anti-TNF-a therapy increases
the risk of infection, including tuberculosis [27]. Infu-
sion reactions are usually mild [28]. Human anti-
chimeric antibody may develop in patients receiving
repeated infusion [29,30], with a controversial role in
hypersensitivity reactions; the combination of infliximab
with low-dose methotrexate may be used to limit the risk
of antibody formation.
Given the well-proven effectiveness of corticosteroids in
the treatment of active pulmonary sarcoidosis, newer
therapies must demonstrate superior efficacy and safety
in order to become the standard of care [11]. This has not
been demonstrated for bioagent therapy, with the
notable exception of infliximab in a limited number of
patients with disease intractable with corticosteroids,
especially those with severe systemic manifestations.
Abbreviation
TNF-a, tumour necrosis factor-alpha.
Competing interests
The authors declare that they have no competing
interests.
Acknowledgements
Financial support was provided by the University of
Lyon. The author is indebted to Jean-François Cordier
(Lyon, France) for critical review of the manuscript.
References
1. Baughman RP, Costabel U, du Bois RM: Treatment of sarcoidosis.
Clin Chest Med 2008, 29:533-48, ix-x.
2. Judson MA: An approach to the treatment of pulmonary
sarcoidosis with corticosteroids: the six phases of treatment.
Chest 1999, 115:1158-65.
3. Baughman RP, Winget DB, Lower EE: Methotrexate is steroid
sparing in acute sarcoidosis: results of a double blind,
randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000, 17:60-6.
4. Lower EE, Baughman RP: Prolonged use of methotrexate for
sarcoidosis. Arch Intern Med 1995, 155:846-51.
5. Utz JP, Limper AH, Kalra S, Specks U, Scott JP, Vuk-Pavlovic Z,
Schroeder DR: Etanercept for the treatment of stage II and III
progressive pulmonary sarcoidosis. Chest 2003, 124:177-85.
6. Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A:
Etanercept for refractory ocular sarcoidosis: results of a
double-blind randomized trial. Chest 2005, 128:1062-47.
7. Saleh S, Ghodsian S, Yakimova V, Henderson J, Sharma OP:
Effectiveness of infliximab in treating selected patients with
sarcoidosis. Respir Med 2006, 100:2053-9.
8. Doty JD, Mazur JE, Judson MA: Treatment of sarcoidosis with
infliximab. Chest 2005, 127:1064-71.
9. Stagaki E, Mountford WK, Lackland DT, Judson MA: The treatment
of lupus pernio: results of 116 treatment courses in 54
patients. Chest 2009, 135:468-76.
Page 4 of 5
(page number not for citation purposes)
f1000 Medicine Reports 2010, 2:13 http://f1000.com/reports/m/2/1310. Baughman RP, Bradley DA, Lower EE: Infliximab in chronic ocular
inflammation. Int J Clin Pharmacol Ther 2005, 43:7-11.
11. Rossman MD, Newman LS, Baughman RP, Teirstein A,
Weinberger SE, Miller W Jr, Sands BE: A double-blinded,
randomized, placebo-controlled trial of infliximab in subjects
with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung
Dis 2006, 23:201-8.
12. Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R,
Albera C, Brutsche M, Davis G, Donohue JF, Muller-Quernheim J,
Schlenker-Herceg R, Flavin S, Lo KH, Oemar B, Barnathan ES:
Infliximab therapy in patients with chronic sarcoidosis and
pulmonary involvement. Am J Respir Crit Care Med 2006, 174:795-
802.
f1000 Factor 4.8 Must Read
Evaluated by Fernando Martinez 24 Oct 2006, Jay H Ryu 05 Dec
2006
13. Wells AU: Infliximab in extrapulmonary sarcoidosis: tantalis-
ing but inconclusive. Eur Respir J 2008, 31:1148-9.
14. Judson MA, Baughman RP, Costabel U, Flavin S, Lo KH, Kavuru MS,
Drent M: Efficacy of infliximab in extrapulmonary sarcoidosis:
results from a randomised trial. Eur Respir J 2008, 31:1189-96.
15. Van den Brande JM, Braat H, van den Brink GR, Versteeg HH,
Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW,
Peppelenbosch MP, van Deventer SJ: Infliximab but not etaner-
cept induces apoptosis in lamina propria T-lymphocytes
from patients with Crohn’sd i s e a s e .Gastroenterology 2003,
124:1774-85.
16. Thielen AM, Barde C, Saurat JH, Laffitte E: Refractory chronic
cutaneous sarcoidosis responsive to dose escalation of TNF-
alpha antagonists. Dermatology 2009, 219:59-62.
17. Marnane M, Lynch T, Scott J, Stack J, Kelly PJ: Steroid-unresponsive
neurosarcoidosis successfully treated with adalimumab. J
Neurol 2009, 256:139-40.
18. Massara A, Cavazzini L, La Corte R, Trotta F: Sarcoidosis
appearing during anti-tumor necrosis factor alpha therapy:
a new “class effect” paradoxical phenomenon. Two case
reports and literature review. Semin Arthritis Rheum 2010,
39:313-9.
19. Metyas SK, Tadros RM, Arkfeld DG: Adalimumab-induced
noncaseating granuloma in the bone marrow of a patient
being treated for rheumatoid arthritis. Rheumatol Int 2009,
29:437-9.
20. Callejas-Rubio JL, Ortego-Centeno N, Lopez-Perez L, Benticuaga MN:
Treatment of therapy-resistant sarcoidosis with adalimu-
mab. Clin Rheumatol 2006, 25:596-7.
21. Almodovar R, Izquierdo M, Zarco P, Javier Quiros F, Mazzucchelli R,
Steen B: Pulmonary sarcoidosis in a patient with ankylosing
spondylitis treated with infliximab. Clin Exp Rheumatol 2007,
25:99-101.
22. González-López MA, Blanco R, González-Vela MC, Fernández-
Llaca H, Rodríguez-Valverde V: Development of sarcoidosis
during etanercept therapy. Arthritis Rheum 2006, 55:817-20.
23. Ishiguro T, Takayanagi N, Kurashima K, Matsushita A, Harasawa K,
Yoneda K, Tsuchiya N, Miyahara Y, Yamaguchi S, Yano R, Tokunaga D,
Saito H, Ubukata M, Yanagisawa T, Sugita Y, Kawabata Y: Develop-
ment of sarcoidosis during etanercept therapy. Intern Med
2008, 47:1021-5.
24. Verschueren K, Van Essche E, Verschueren P, Taelman V,
Westhovens R: Development of sarcoidosis in etanercept-
treated rheumatoid arthritis patients. Clin Rheumatol 2007,
26:1969-71.
f1000 Factor 6.0 Must Read
Evaluated by Tetsuo Shiohara 21 Jul 2008
25. Belkhou A, Younsi R, El Bouchti I, El Hassani S: Rituximab as a
treatment alternative in sarcoidosis. Joint Bone Spine 2008,
75:511-2.
26. Wasfi YS, Rose CS, Murphy JR, Silveira LJ, Grutters JC, Inoue Y,
Judson MA, Maier LA: A new tool to assess sarcoidosis severity.
Chest 2006, 129:1234-45.
27. Brassard P, Kezouh A, Suissa S: Antirheumatic drugs and the risk
of tuberculosis. Clin Infect Dis 2006, 43:717-22.
28. Vultaggio A, Matucci A, Parronchi P, Rossi O, Palandri F, Romagnani S,
Maggi E: Safety and tolerability of infliximab therapy: sugges-
tions and criticisms based on wide clinical experience. Int J
Immunopathol Pharmacol 2008, 21:367-74.
29. Miele E, Markowitz JE, Mamula P, Baldassano RN: Human anti-
chimeric antibody in children and young adults with
inflammatory bowel disease receiving infliximab. J Pediatr
Gastroenterol Nutr 2004, 38:502-8.
30. van der Bijl AE, Breedveld FC, Antoni CE, Kalden JR, Kary S,
Burmester GR, Beckmann C, Unnebrink K, Kupper H: An open-
label pilot study of the effectiveness of adalimumab in
patients with rheumatoid arthritis and previous infliximab
treatment: relationship to reasons for failure and anti-
infliximab antibody status. Clin Rheumatol 2008, 27:1021-8.
Page 5 of 5
(page number not for citation purposes)
f1000 Medicine Reports 2010, 2:13 http://f1000.com/reports/m/2/13